Introduction {#s1}
============

Tobacco use is a major global health problem with enormous economic and social costs. It remains the leading cause of preventable death worldwide, with tobacco-related illnesses estimated to kill more than 6 million people annually ([@bib29]). In the United States, the direct and indirect financial costs of smoking are estimated at more than \$300 billion each year ([@bib26]; [@bib30]). Adolescents are particularly at risk for initiating tobacco use, with a vast majority of all smokers beginning at age 18 or younger ([@bib26]). A growing body of evidence from both human and animal studies indicates that adolescents are more susceptible than adults to the cellular and behavioral effects of nicotine, the main addictive component of tobacco ([@bib1]; [@bib3]; [@bib16]; [@bib25]).

Nicotine modifies dopamine (DA) signaling in key regions of the brain's reward system ([@bib11]; [@bib5]). Human neuroimaging studies of smokers have shown that exposure to nicotine alters reward-related activity in dopaminergic reward regions ([@bib19]). Moreover, in rodents, while nicotine is known to potentiate excitatory synaptic connections to DA neurons in the reward-related ventral tegmental area (VTA) ([@bib17]; [@bib21]), the precise molecular mechanism underlying nicotine-induced long-term potentiation (LTP) remains unclear. In a companion article ([@bib10]), we found that the translation initiation factor eIF2α regulates adolescent vulnerability to the synaptic and behavioral effects of cocaine. Briefly, adolescent (5 weeks old) mice proved to be more sensitive to a lower dose of cocaine than adult (3--5 months old) mice with regard to reduced phosphorylation of eIF2α, the induction of LTP, and cocaine-induced behavior \[conditioned place preference (CPP), a common behavioral task that reflects behavioral reinforcement underlying the development of drug addiction\] ([@bib13]). Consistent with these findings, genetic and pharmacological reduction in p-eIF2α-mediated translational control increased the susceptibility of adult mice to the synaptic and behavioral effects of cocaine, making adult mice resemble adolescents in this respect. Furthermore, other drugs of abuse (including nicotine), that are known to induce LTP in the VTA ([@bib21]), also reduced p-eIF2α in the VTA ([@bib10]), thus highlighting the role of p-eIF2α as a common effector implicated in the initiation of addictive behavior. In the present study, we found that, like cocaine, mice with reduced p-eIF2α-mediated translation are more susceptible to nicotine-evoked synaptic potentiation in the VTA. Furthermore, using functional magnetic resonance imaging (fMRI) in humans, we identified a functional genetic variation in the promoter of the *Eif2s1* gene encoding eIF2α that alters brain responses to rewarding stimuli in human tobacco smokers.

Results and discussion {#s2}
======================

Adolescent mice are more susceptible than adult mice to nicotine-induced LTP in VTA DA neurons {#s2-1}
----------------------------------------------------------------------------------------------

In the accompanying study, we found that adolescent mice are more susceptible to cocaine-induced synaptic potentiation in VTA DA neurons. We therefore asked whether this was also true for nicotine. To answer this question, we measured glutamate-mediated excitatory postsynaptic currents (EPSCs) in VTA DA neurons from adolescent (5 weeks old) and adult (3--5 months old) mice 24 hr after single intra-peritoneal (i.p.) injection of either saline or different doses of nicotine. The peak amplitudes of the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) and *N*-methyl D-aspartate receptor (NMDAR)-mediated components of the evoked EPSCs (recorded at +40 mV) were isolated and used to calculate the AMPAR/NMDAR ratio as described ([@bib10]). An increase in this ratio was taken as an index of LTP. We found that a relatively low dose of nicotine (0.4 mg/kg i.p.) was sufficient to induce LTP in VTA DA neurons from adolescent mice, but not in adult mice ([Figure 1a, b](#fig1){ref-type="fig"} and [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). By contrast, a higher dose of nicotine (1.0 mg/kg) was required to elicit comparable LTP in VTA DA neurons from adult mice ([Figure 1b](#fig1){ref-type="fig"} and [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). Thus, like cocaine, nicotine induces LTP in VTA DA neurons at a significantly lower dose in adolescent mice.10.7554/eLife.12056.003Figure 1.Reduced p-eIF2α-mediated translational control increases the susceptibility to nicotine-induced LTP.(**a-b**) Left, Representative traces of AMPAR and NMDAR EPSCs recorded from VTA DA neurons 24 hr after i.p. injection of saline or the indicated dose of nicotine. A relatively low dose of nicotine (0.4 mg/kg) induced LTP, shown by an increase in AMPAR/NMDAR ratio in VTA DA neurons (**a**, Right, *P\<*0.01, *n*=6,6 saline/0.4 mg/kg nicotine, *t*~10~=4.026) from adolescent mice (5 weeks old), but not in those from adult mice (3--5 months old, b, Right, *P*=0.802, *n*=6/7/6 saline/0.4 mg/kg nicotine/1.0 mg/kg nicotine, *F*~2,16~=9.029). A higher dose of nicotine (1.0 mg/kg) was required to increase the AMPAR/NMDAR ratio in VTA DA neurons from adult mice (**b**, Right, *P\<*0.05 vs. saline or 1.0 mg/kg nicotine, *n*=6/7/6 saline/0.4 mg/kg nicotine/1.0 mg/kg nicotine, *F*~2,16~=9.029). (**c-d**) A low dose of nicotine (0.4 mg/kg) reduced p-eIF2α in the VTA of adolescents (**c,** *P*\<0.05, *n*=9/5 saline/0.4 mg/kg nicotine, *t*~12~=2.479), but not adult mice (**d,** *P*=0.5710, *n*=7/11 saline/0.4 mg/kg nicotine, *t~16~*=0.5784). (**e**) A higher dose of nicotine (1 mg/kg) was required to reduce p-eIF2α in VTA of adult mice (*P*\<0.01, *n*=11/5 saline/1 mg/kg nicotine, *t*~14~=3.428). (**f**) A low dose of nicotine (0.4 mg/kg) failed to induce LTP in VTA DA neurons from adult WT (*Eif2s1^S/S^*) mice (Left, *P*=0.964, *n*=5 per group, *t*~8~=0.05), but elicited significant LTP in adult *Eif2s1^S/A^* mice (Right, *P*=0.003, *n*=5 per group, *t*~8~=6.73). (**g**) A low dose of nicotine (0.4 mg/kg) induced LTP in ISRIB-injected adult mice compared to vehicle-injected mice (*P*\<0.001, *n*=7/7 nicotine+vehicle/nicotine+ISRIB, *t*~12~=5.222).**DOI:** [http://dx.doi.org/10.7554/eLife.12056.003](10.7554/eLife.12056.003)10.7554/eLife.12056.004Figure 1---figure supplement 1.Adolescent mice are more susceptible than adult mice to nicotine-induced synaptic potentiation.Adolescent (5 weeks old, n=6--7 per group) or adult mice (3--5 months old, n=6--7 per group) were i.p-injected with saline or nicotine at indicated doses and whole-cell recordings were performed in VTA DA neurons. An increase in the AMPAR/NMDAR ratio (an index of LTP) was induced with the 0.4 mg/kg dose of nicotine (F~2,32~=4.34, P\<0.01 vs. saline) in adolescent mice, whereas 1.0 mg/kg was required for a significant increase in adults (F~2,32~=4.34, P\<0.05 vs. saline or 0.4 mg/kg nicotine).**DOI:** [http://dx.doi.org/10.7554/eLife.12056.004](10.7554/eLife.12056.004)

Like adolescent mice, adult mice with reduced eIF2α-mediated translational control are more susceptible to nicotine-evoked LTP {#s2-2}
------------------------------------------------------------------------------------------------------------------------------

In the accompanying article ([@bib10]) we found that a low dose of cocaine reduces phosphorylation of eIF2α only in the VTA of adolescent mice. To test whether the same is true for nicotine, we injected adolescent and adult mice with a low (0.4 mg/kg) and a relatively high (1 mg/kg) dose of nicotine, respectively. Consistent with our findings with cocaine, we found that a low dose of nicotine (0.4 mg/kg) reduced p-eIF2α only in the VTA of adolescent mice ([Figure 1c, d](#fig1){ref-type="fig"}), whereas a higher dose of nicotine (1 mg/kg) was required to reduce p-eIF2α in the VTA of adult mice ([Figure 1e](#fig1){ref-type="fig"}). Thus, like cocaine, low doses of nicotine selectively reduce p-eIF2α in the VTA of adolescent mice, highlighting the involvement of p-eIF2α-mediated translational control during this period of heightened vulnerability to the effects of drugs of abuse.

Based on these findings, we predicted that adult mice with reduced p-eIF2α-mediated translational control would be more susceptible to the synaptic effects of nicotine. To test this prediction, we injected both adult control and *Eif2s1^S/A^* mice (in which p-eIF2α in VTA is reduced by about 50% because the phosphorylation site is mutated to alanine ([@bib10]) with a low dose of nicotine (0.4 mg/kg i.p.). This low dose does not typically induce LTP in adult wild-type (WT) mice ([Figure 1b](#fig1){ref-type="fig"}), and as expected, it failed to induce LTP in control WT *Eif2s1^S/S^* mice ([Figure 1f](#fig1){ref-type="fig"}). By contrast, the same low dose of nicotine elicited LTP in adult *Eif2s1^S/A^* mice ([Figure 1f](#fig1){ref-type="fig"}). Thus, like adolescent mice, adult mice with reduced eIF2α phosphorylation are more susceptible to the synaptic effects of nicotine.

To further support these findings, we used the recently discovered small molecule ISRIB ([@bib24]), which selectively blocks p-eIF2α-mediated translational control ([@bib24]). Briefly, adult WT mice were acutely injected with both ISRIB (2.5 mg/kg) and a low dose of nicotine (0.4 mg/kg) and LTP was recorded in VTA DA neurons 24 hr later. Indeed, a low dose of nicotine (0.4 mg/kg) induced LTP only in adult mice in which p-eIF2α-mediated translation was blocked pharmacologically with ISRIB ([Figure 1g](#fig1){ref-type="fig"}). Hence, like adolescent mice, adult mice with reduced p-eIF2α-mediated translational control are more susceptible to nicotine-induced LTP. Thus, our findings that reducing p-eIF2α-mediated translational control renders animals more susceptible to the effects of both cocaine ([@bib10]) and nicotine underscores a key role of p-eIF2α as a common regulator of drug-induced synaptic potentiation and behavior.

Polymorphic variation in the *Eif2s1* gene affects reward signaling measured by fMRI in human tobacco smokers {#s2-3}
-------------------------------------------------------------------------------------------------------------

Several studies in rodents have shown that certain genes or signaling pathways are implicated in the behavioral effects of drugs of abuse ([@bib18]), but their clinical relevance to humans remains unknown. Because p-eIF2α crucially regulates drug-induced changes in synaptic strength and behavior in mice, we sought to determine whether single nucleotide polymorphisms (SNPs) in the eIF2α signaling pathway could be associated with reward-induced changes in neuronal activity in human smokers. Indeed, by studying specific SNPs chosen on the basis of this hypothesis, we bypassed the problems inherent to large exploratory data analyses and multiple comparisons typical of genome-wide association studies. In this way we increased the chances of finding true effects related to biological processes, while reducing the possibility of false positives.

According to neuroimaging studies, neuronal activity in key reward areas of the human brain is strongly associated with indices of drug use ([@bib20]). We therefore measured reward-mediated activity in the caudate and putamen---brain regions with crucial reward-related functional connections to the VTA ([@bib14])---of tobacco smokers and non-smokers ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). To elicit reward responses in the fMRI scanner, participants received small (1 mL) squirts of sweet juice orally while functional MRI images of their brains were collected (see Material and Methods and [Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}). Consistent with previous findings in cocaine and tobacco users ([@bib19]; [@bib20]), we observed significantly lower reward-induced activity in the caudate and putamen of smokers ([Figure 2a and c](#fig2){ref-type="fig"}), indicating that smokers find sweet drinks less rewarding. More importantly, we identified an SNP (rs10144417) in the *Eif2s1* (eIF2α) gene that revealed an interaction between genotype and smoking status. While smokers carrying the AG/GG genotype showed lower reward-dependent activity compared with that of the AA smokers, such activity did not differ between non-smokers of both genotypes ([Figure 2d](#fig2){ref-type="fig"}). These data indicate that rs10144417 in the *Eif2s1* gene is associated with both reward signaling and tobacco use.10.7554/eLife.12056.005Figure 2.The effect of a single nucleotide polymorphism (SNP) in the promoter of the *Eif2s1* gene on reward-dependent striatal activity in human tobacco smokers.(**a-c**) Reward-related activity in caudate/putamen is lower in smokers than non-smokers (**b,** *P*\<0.01, n=33/55, *t*~86~=2.678). (**b-c**) Transverse (**b**) and sagittal (**c**) views of significant fMRI BOLD signal in caudate/putamen of non-smokers compared to smokers in response to juice reward. (**d**) Interaction between smoking and rs10144417 genotype (*P*\<0.05, F~1,86~=5.836). (**e**) Partial alignment of *Eif2s1* promoter sequences in human and related animals. Note high level of nucleotide conservation: the rs10144417 SNP is indicated in blue and the non-conserved nucleotides in red. (**f**) Schematic of firefly luciferase reporter constructs, in which a 5-kb *Eif2s1* promoter fragment containing either the A or G allele was cloned upstream of the firefly luciferase gene in the p15Amp reporter vector. A renilla luciferase reporter was co-transfected with reporters containing the A or G variant and firefly luciferase (Fluc) activity was normalized to renilla (Rluc) activity. (**g**) Effects of A and G variants of SNP rs10144417 on the transcriptional activity of the *Eif2s1* promoter as assessed by a luciferase reporter assay in HEK-293 cells. The data are from three independent experiments (*P*\<0.001, *n*=6 per group, *t~10~*=5.405). (****h**)** Western blotting showing that overexpression of *Eif2s1* (pRc/CMV-*Eif2s1*) increased eIF2α levels compared to control (vector alone pRc/CMV). (**i**) Diagram of the 5′ UTR-*Ophn1-*Fluc reporter, which consists of the 5'UTR of *Ophn1* mRNA fused to the coding region of Firefly luciferase (Fluc). A renilla luciferase (Rluc) reporter vector was co-transfected into HEK293T as a transfection control. (**j**) Overexpression of *Eif2s1* reduced expression of 5′ UTR-*Ophn1*-Fluc (*P*\<0.01, n=6, *t~10~*=3.9425).**DOI:** [http://dx.doi.org/10.7554/eLife.12056.005](10.7554/eLife.12056.005)10.7554/eLife.12056.006Figure 2---figure supplement 1.Demographic information of human participants involved in fMRI studies.(**a**) Table showing the number of participants by gender, age, and smoking status carrying the A or the G variant in the *Eif2s1* gene. (**b**) Table showing the number of participants by their self-reported ethnicities The participants have no history of any other drug dependance.**DOI:** [http://dx.doi.org/10.7554/eLife.12056.006](10.7554/eLife.12056.006)10.7554/eLife.12056.007Figure 2---figure supplement 2.fMRI recording paradigm and reward-stimulus pairing in human smokers.(**a**) The fMRI recording session consisted of four 5--7 min blocks of light-juice pairings. A self-paced break ("inter-run interval") was included between runs to allow participants to ask any questions and to allow the investigators to provide feedback on participant motion within the scanner. (**b**) A total of fifty-five light-juice (1 mL) pairings were presented. The delay between light and juice was 7 s.**DOI:** [http://dx.doi.org/10.7554/eLife.12056.007](10.7554/eLife.12056.007)10.7554/eLife.12056.008Figure 2---figure supplement 3.ATF4-Luciferase construct design and activity with *Eif2s1*.(**a**) Diagram of the 5 UTR-ATF4 Fluc reporter, which consists of the 5'UTR of ATF4 mRNA fused to the coding region of Firefly luciferase (Fluc). A renilla luciferase (Rluc) reporter vector was co-transfected into HEK293T as a transfection control. (**b**) Overexpression of Eif2s1 reduced expression of 5 UTR-ATF4-Fluc (*P*\<0.0001, *n*=4 per group, *t~6~*=11.33).**DOI:** [http://dx.doi.org/10.7554/eLife.12056.008](10.7554/eLife.12056.008)

In silico analysis revealed that rs10144417 spans a highly conserved region of the *Eif2s1* promoter ([Figure 2e](#fig2){ref-type="fig"}). To examine the functional effect of the A/G polymorphism (rs10144417) at this site, we measured firefly luciferase reporter activity ex-vivo using a 5 kilobase (kb) segment of the *Eif2s1* promoter ([Figure 2f](#fig2){ref-type="fig"}). Briefly, human embryonic kidney (HEK293T) cells were co-transfected with a firefly luciferase reporter (Fluc) containing either the A or G variant and a renilla luciferase reporter (Rluc), which was used as a transfection control. We found that, compared to the A variant, the normalized G variant Fluc/Rluc ratio was significantly increased (\~40%, [Figure 2g](#fig2){ref-type="fig"}), reflecting increased expression of *Eif2s1*. To determine whether overexpression of *Eif2s1* could affect p-eIF2α--mediated translational control, we co-expressed in HEK293T cells *Eif2s1* ([@bib7]) ([Figure 2h](#fig2){ref-type="fig"}), a 5'UTR-*Ophn1* firefly luciferase reporter (5'UTR-*Ophn1*-Fluc; [Figure 2i](#fig2){ref-type="fig"}), whose translation is known to be enhanced by conditions that increase p-eIF2α ([@bib6]), and a renilla Luciferase reporter (Rluc), which was used to calculate the relative Fluc/Rluc translation ratio. Strikingly, increased expression of *Eif2s1* significantly reduced the normalized Fluc/Rluc ratio, indicating a significant reduction in translation of *Ophn1* mRNA ([Figure 2j](#fig2){ref-type="fig"}). Additionally, expression of *Eif2s1* selectively reduced 5'UTR-*Ophn1*-Fluc activity, but had no effect on Rluc activity (data not shown). These data were further supported by our findings that overexpression of *Eif2s1* also reduced translation of a 5'UTR-*Atf4* firefly luciferase reporter ([Figure 2---figure supplement 3](#fig2s3){ref-type="fig"}), which is typically up-regulated by increased p-eIF2α ([@bib24]; [@bib15]). Hence, overexpression of the alpha subunit of eIF2 (*Eif2s1*) reduces p-eIF2α--mediated translation.

The mechanism by which increased expression of *Eif2s1* inhibits p-eIF2α--mediated translation remains to be determined. Several different mechanisms could be at play. Overexpression of *Eif2s1* could affect eIF2α-mediated translation by altering: a) the assembly of eIF2 complex \[eIF2 is a heterotrimer consisting of an alpha (encoded by *Eif2s1)*, a beta (encoded by *Eif2s2*), and a gamma subunit (encoded by *Eif2s3*), b) the binding of eIF2 to key regulatory proteins (e.g., eIF2B and/or eIF5), or c) by titrating the phosphorylated alpha subunit away from the eIF2 complex. Moreover, overexpression of *Eif2s1* could alter the expression of a given eIF2α kinase or phosphatase. Such compensatory translational homeostatic mechanisms have been observed when the levels of key translation initiation factors (e.g., eIF4E, 4E-BPs, PABP, Paips) are either increased or decreased ([@bib12]; [@bib31]; [@bib32]).

Collectively, our mouse and human data suggest that reduced p-eIF2α-mediated translational control mediates a genetic predisposition to greater risk for drug-induced changes in synaptic strength, which may account for the greater vulnerability of adolescents, even as first time drug users. For instance, mice with reduced eIF2α-mediated translation are more susceptible to nicotine-induced changes in synaptic function. Similarly, smokers carrying the G variant, who also have reduced eIF2α-mediated translation, show reduced reward-induced activity in the caudate and putamen, suggesting that such individuals are likely to consume more drugs to obtain reward activity comparable to that of non-smokers. Finally, these insights may hold promise for new p-eIF2α-based approaches to treating drug abuse.

Materials and methods {#s3}
=====================

Mice {#s3-1}
----

All experiments were conducted on male and female mice from the C57BL/6 background. *Eif2s1^S/A^*mice were previously described ([@bib6]). Mice were kept on a 12h/12 hr light/dark cycle (lights on at 7:00 am) and had access to food and water *ad libitum*. Animal care and experimental procedures were approved by the institutional animal care and use committee (IACUC) at Baylor College of Medicine, according to NIH Guidelines.

No statistical methods were used to predetermine sample sizes. All sample sizes met the criteria for corresponding statistical tests---our sample sizes are similar to those reported in previous publications ([@bib2]; [@bib27]).

Drug treatment {#s3-2}
--------------

Nicotine was dissolved in 0.9% saline and injected at a volume of 5 ml/kg. (-)-Nicotine hydrogen tartrate was obtained from Sigma-Aldrich (St. Louis, MO). ISRIB (provided by P. Walter) was dissolved in DMSO and further diluted in PEG-400 (1:1 ratio) as previously described ([@bib24]). For both electrophysiological and behavioral experiments, ISRIB (2.5 mg/kg) or vehicle (DMSO/PEG-400, 2 ml/kg) was injected 90 min before nicotine or control saline injections.

Slice electrophysiology {#s3-3}
-----------------------

Electrophysiological recordings were performed as previously described ([@bib27]), investigators blind to genotype. Each electrophysiological experiment was replicated at least three times. Briefly, mice were anesthetized with a mixture of ketamine (100 mg/kg), xylazine (10 mg/kg), and acepromazine (3 mg/kg). Mice were transcardially perfused with an ice-cold, oxygenated solution containing (in mM) NaCl, 120; NaHCO~3~, 25; KCl, 3.3; NaH~2~PO~4~, 1.2; MgCl~2~, 4; CaCl~2~, 1; dextrose, 10; sucrose, 20. Horizontal slices (225--300 μm thick) containing the VTA were cut from the brains of adolescent (5 week old) or adult (3--5 month old) C57BL/6J mice using a vibrating tissue slicer (VF-100 Compresstome, Precisionary Instruments, San Jose, CA, or Leica VT 1000S, Leica Microsystems, Buffalo Grove, IL). Slices were next incubated at 34°C for 40 min then kept at room temperature for at least 30 min before they were transferred to a recording chamber where they were continuously perfused with artificial cerebrospinal fluid (ACSF) at 32°C at a flow rate of 2--3 ml/min. The recording ACSF differed from the cutting solution in regard to the concentration of MgCl~2~ (1 mM) and CaCl~2~ (2 mM). Recording pipettes were made from thin-walled borosilicate glass (TW150F-4, WPI, Sarasota, FL). After filling with intracellular solution (in mM): 117 CsMeSO3; 0.4 EGTA; 20 HEPES; 2.8 NaCl, 2.5 ATP-Mg 2.0; 0.25 GTP-Na; 5 TEA-Cl, adjusted to pH 7.3 with CsOH and 290 mOsmol/l, they had a resistance of 3--5 MΩ.

Data were obtained with a MultiClamp 700B amplifier, digitized at 20 kHz with a Digidata 1440A, recorded by Clampex 10 and analyzed with Clampfit 10 software (Molecular Devices). The signals were filtered online at 4 kHz with a Bessel low-pass filter. A 2 mV hyperpolarizing pulse was applied before each EPSC to evaluate the input and access resistance (Ra). Data were discarded when Ra was either unstable or greater than 25 MΩ, holding current was \> 200 pA, input resistance dropped \> 20% during the recording, or baseline EPSCs changed by \> 10%. Traces illustrated in Figures are averages of 10--15 consecutive traces.

After establishing a gigaohm seal (\> 2 GΩ) and recording stable spontaneous firing in cell-attached voltage clamp mode (at -70 mV holding potential), cell phenotype was determined by measuring the width of the action potential ([@bib8]). AMPAR/NMDAR ratios were calculated as previously described ([@bib27]). Briefly, neurons were voltage-clamped at +40 mV until the holding current stabilized (at \< 200 pA). Monosynaptic EPSCs were evoked at 0.05 Hz with a bipolar stimulating electrode placed 50--150 μm rostral to the lateral VTA. Picrotoxin (100 μM) was added to the recording ACSF to block GABA~A~R-mediated IPSCs. After recording the dual-component EPSC, DL-AP5 (100 μM) was bath-applied for 10 min to remove the NMDAR component, which was then obtained by offline subtraction of the remaining AMPAR component from the original EPSC. The peak amplitudes of the isolated components were used to calculate the AMPAR/NMDAR ratios. Picrotoxin and DL-AP5 were purchased from Tocris Bioscience and all other reagents and experimental compounds were obtained from Sigma-Aldrich.

Plasmid construction, transfection and luciferase assay {#s3-4}
-------------------------------------------------------

The *Eif2s1* promoter region was cloned out of human BAC RP11-713C11 using primers 5' sense 5'-ATTCGCGAGGGAAAGATTTCAATTC-3', and antisense 5'-TCTGCAATTTAAACAAAAGAATTAAGTAAGT-3'. The firefly luciferase was amplified from Luciferase-pcDNA3 (Promega, Madison, WI) using the sense primer 5'-ACTTACTTAATTCTTTTGTTTAAATTGCAGAATGGAAGACGCCAAAAACATAAAG3' and antisense primer 5'-ACATTTCCCCGAAAAGTGCCACCTGCCATAGAGCCCACCGCATCCCCAG-3'. The p15a_Amp was amplified from pWSTK6 using sense primer 5'-CAGGTGGCACTTTTCGGGGAAATGT-3' and antisense primer 5'-GAATTGAAATCTTTCCCTCGCGAATGCTAGCGGAGTGTATACTGGCTTAC-3'. All three fragments were Gibson cloned and confirmed by DNA sequencing. The resulting plasmid (*Eif2s1*-A-luc) carries the A in the SNP rs101444417 position up-stream of firefly luciferase. In a mutagenesis reaction using the *Eif2s1*-A-luc plasmid as template and sense primer 5'-GGTTACTTAGCTAAAGCTAAGGTAGCGAGAAACAGTACTTTTCAG-3' and antisense primer 5'-CCTGAAAAGTACTGTTTCTCGCTACCTTAGCTTTAGCTAAGTAACC-3', we generated a clone (*Eif2s1*-G-luc) containing the G in the SNP rs101444417 position up-stream of firefly luciferase. HEK293T cells (a widely used human cell line) were grown in 24-well plates in Gibco DMEM+Glutamax (Life Technologies) supplemented with 10% FBS, 100 units of Pen/Strep per ml. *Eif2s1*-G-luc and *Eif2s1*-A-luc were co-transfected with a renilla luciferase (Rluc) plasmid pRL-TK (Promega, Madison, WI) into HEK293T cells at 50--80% confluency using Lipofectomine LTX plus (Life Technologies). pRc/CMV and pRc/CMV-*eIF2s1* vectors, which were previously reported ([@bib7]), were co-transfected with 5'UTR-*Ophn1*-Fluc and RLuc into HEK293T, as described above. Similarly 5'UTR-*Atf4*-Fluc ([@bib24]) was co-transfected with RLuc into HEK293T cells. 24 hr after transfection, cell extracts were prepared in passive lysis buffer and samples were collected in pre-chilled microcentrifuge tubes and lysed in homogenizing buffer \[200 mM HEPES, 50 mM NaCl, 10% Glycerol, 1% Triton X-100, 1 mM EDTA, 50 mM NaF, 2 mM Na~3~VO~4~, 25 mM β-glycerophosphate, and EDTA-free complete ULTRA tablets (Roche, Indianapolis, IN)\].

Human functional MRI data {#s3-5}
-------------------------

All procedures were approved by Baylor College of Medicine Internal Review Board. Smokers and non-smokers were recruited from the Houston metropolitan area via fliers, newspaper, and internet advertisements and received a small monetary compensation. All participants were pre-screened to rule out non-tobacco substance dependence or MRI contraindications (e.g. head injuries, foreign metal in the body, claustrophobia, or pregnancy). Smokers currently seeking cessation treatment were also excluded. Smoking history and dependence were evaluated using the Fagerström Test for Nicotine Dependence (FTND) ([@bib9]), Shiffman-Jarvik Withdrawal Questionnaire (SJWQ) ([@bib23]), and the Positive and Negative Affect Schedule (PANAS) ([@bib28]). All participants read and signed an Informed Consent to participate in this research protocol.

No statistical methods were used to predetermine sample sizes but sample sizes were similar to those previously reported ([@bib19]; [@bib22]). The subjects were either smokers (*n*=35, average age=43.26 years ± 12.19 years, 77.1% males, 22.9% females, smoking at least 10--15 cigarettes per day and had smoked for at least the past year) or non-smokers (*n*=54, average age=31.37 ± 11.60 years, 44.4% males 55.5% females, lifetime incidence of smoking less than 50 cigarettes or no cigarettes for the last year). For more information on participant demographic, see [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}.

Participants were scanned in 3T Siemens Trio scanners in the Center for Advanced MRI at Baylor College of Medicine. Structural MPRAGE images were collected as 160 1×1×1 mm axial slices (TE=2.66 ms, TR=1200 ms, flip angle=12°, 256 × 256 matrix) while functional images were collected as 2x2x2 mm epi scans (TR 2 s, TE 40 ms) over a 44 mm "slab" covering the regions of interest. Light-juice pairings were presented during functional scanning using ePrime software (Psychology Software Tools, Sharpsburg, PA). For each of a maximum of 55 light-juice pairings, a Standard Infuse/Withdraw Harvard 33 Twin Syringe Pump (Harvard Apparatus, Holliston, MA) delivered 1 mL of juice 7s after a light cue. Prior to scanning, participants were given a choice of sugar-free sweet drinks (such as lemonade, iced tea with peach or fruit punch, and the preferred juice was given during scanning). fMRI data were analyzed using a standard AFNI processing stream ([@bib4]). Briefly, the first four TRs were removed to establish a stable baseline. Data were then corrected for slice-time acquisition (3dTshift), aligned to the first image and measured for motion (3dvolreg), registered to the high resolution MPRAGE, and transformed to MNI space using a single spatial transform (\@auto_tlrc, 3dAllineate). A 4.5 mm smoothing kernel was applied in 3dmerge and submitted to a General Linear Model (GLM) regression in 3dDeconvolve. GLM regressors for linear, quadratic, and cubic linear trends; x, y, z, roll, pitch, and yaw motion parameters; and the two stimulus conditions: visual cue and juice reward were included. An analysis of the interaction between smoker/non-smoker group and genotype (e.g. rs10144417 AA vs. GG/AG) was performed using a 3D multivariate model (3dMVM) and family-wise error correction. The percent signal change in BOLD activation for individual subjects was extracted from caudate and putamen regions of interest (ROIs) and restricted to those voxels identified as having a *P*\<0.05 and alpha\<0.05 in the multivariate model of group by genotype interaction. No effect of age, number of years smoking, average number of cigarettes per day, gender, or ethnicity was observed in the fMRI analysis.

Human genotype {#s3-6}
--------------

DNA was isolated from buccal swabs and genotyping was completed using Illumina (San Diego, CA) HumanOmniExpress-12 v1.1 BeadChip arrays (cat\# WG-312-1120) containing approximately 741K SNPs. Genomic DNA (200 ng) from each sample was processed following Illumina's Infinium HD Ultra Assay protocol. BeadChip images were captured using Illumina iScan System. The Illumina chip contained the *Eif2s1* rs10144417 SNP (Global minor allele frequency MAF:0.2993). fMRI activity was studied according to the genotype of analyzed subjects. Subjects with AG and GG genotypes were pooled for analysis and compared to subjects with the AA genotype using AFNI's statistical software.

Statistical analyses {#s3-7}
--------------------

All data are presented as mean ± s.e.m. Statistical analyses were performed with SigmaPlot (Systat Software). Data distribution normality and homogeneity of variance were assessed by Shapiro-Wilk and Levene tests, respectively. The statistics were based on the two-sided Student's t test, or one- or two-way ANOVA with Tukey's HSD (or HSD for unequal sample sizes where appropriate) to correct for multiple *post hoc* comparisons. Within-groups variation is indicated by standard errors of the mean of each distribution, which are depicted in the graphs as error bars. *P*\<0.05 was considered significant (\**P*\<0.05, \*\**P*\<0.01, \*\*\**P*\<0.001, \*\*\*\**P*\<0.0001).
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your work entitled \"eIF2α regulates nicotine-evoked synaptic potentiation in mice and reward-induced neuronal responses in human smokers\" for consideration by *eLife*. Your article has been reviewed by two peer reviewers, and the evaluation has been overseen by a Reviewing Editor and a Senior Editor.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

1\) The authors should be clearer about what their experiments show and do not show. For example, they do not have any evidence, as they claim, that \"reduced p-eIF2α-mediated translational control is a genetic modifier of risk for drug addiction\". The study did not seem to look at drug addiction in either mice or human subjects. Instead the authors studied reward responses. There is an important and clear distinction between the two.

2\) Regarding the results from rodents, the authors should provide a direct evidence for the phosphorylation level of eIF2alpha in adolescent mice versus adult ones, as well as after nicotine treatment. It is arguable that changes in eIF2 α activity can underline the differential effect nicotine-mediated in adolescent mice compared to adults. A direct assay exploring this issue, if it can be performed rapidly, could be of relevance to further support the electrophysiological finding.

3\) Did the authors test the higher dose of nicotine in adolescent mice? It would be an additional and interesting information whether in adolescent mice the nicotine effect has already reached a saturated level or the LTP could further increase at higher concentration of nicotine.

4\) Although the nicotine-mediated effect on AMPAR/NMDAR ratio is clearly significant, the number of 4 observations is too low and only slightly above the minimal required number for the statistical power. Strong recommendation to increase the N.

5\) The selection criteria of participants, especially smoker subjects, should be specified. Did they have history of any other drug dependence? A table depicting the participants\' demographics would be useful for readers.

6\) The presentation of the polymorphism data was confusing. Especially the relationship between the mouse work and human results should be made clear and caveats in the link pointed out. It is important to note that the strength of the paper is the connection between the mouse and human data and anything that would strengthen that connection would consequently strengthen the paper. The relation between FLUC and RLUC assays is also murky and confusing. This should also be explained better. Finally, the reviewers wonder which mechanisms could cause increased expression of Eif2s inhibits p-eIF2α−mediated translation.
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Author response

*1) The authors should be clearer about what their experiments show and do not show. For example, they do not have any evidence, as they claim, that \"reduced p-eIF2α-mediated translational control is a genetic modifier of risk for drug addiction\". The study did not seem to look at drug addiction in either mice or human subjects. Instead the authors studied reward responses. There is an important and clear distinction between the two.*

We agree with the reviewers and have now replaced "drug addiction" by "drug-induced synaptic potentiation and behavior". The sentence quoted above now reads as follows: "Collectively, our mouse and human data suggest that reduced p- eIF2α-mediated translational control mediates a genetic predisposition to greater risk for drug-induced changes in synaptic strength, which may account for the greater vulnerability of adolescents, even as first time drug users" (Results and Discussion).

*2) Regarding the results from rodents, the authors should provide a direct evidence for the phosphorylation level of eIF2alpha in adolescent mice versus adult ones, as well as after nicotine treatment. It is arguable that changes in eIF2α activity can underline the differential effect nicotine-mediated in adolescent mice compared to adults. A direct assay exploring this issue, if it can be performed rapidly, could be of relevance to further support the electrophysiological finding.*

As recommended by the reviewers, we administered different doses of nicotine to adult and adolescent mice and found that a low dose of nicotine reduces eIF2α phosphorylation in the VTA of adolescents, but not adult mice (see new [Figure 1C-E](#fig1){ref-type="fig"} and subsection "Like adolescent mice, adult mice with reduced eIF2α-mediated translational control are more susceptible to nicotine-evoked LTP", first paragraph). Thus, like cocaine, our new experiments with nicotine highlight the involvement of p-eIF2α phosphorylation-mediated translational control during this period of heightened vulnerability to the effects of drugs of abuse.

While basal p-eIF2α levels are similar in the VTA of adults and adolescent mice (see new Figure 1---figure supplement 4 in the accompanying paper by Huang et al.), phosphorylation of eIF2α in the brain is dynamically regulated by kinases: double-stranded RNA-dependent kinase (PKR), general control non-derepressible 2 (GCN2), PKR-like endoplasmic reticulum kinase (PERK) and Heme-regulated eIF2α kinase (HRI); as well as by two phosphatase complexes: protein phosphatase 1/growth arrest and DNA-damage inducible protein (PP1/GADD34) and PP1/constitutive reverter of eIF2α phosphorylation (PP1/CReP)~1,2~. Thus, in the Discussion section of our accompanying paper (p. 12), we speculate that nicotine (and other drugs of abuse) either inhibit the activity of a given eIF2α kinase or promote the activity of eIF2α phosphatases, processes to which we suspect adolescents are more prone. We are currently investigating the precise mechanism by which drugs of abuse decrease p-eIF2α in the VTA and other reward-related areas.

*3) Did the authors test the higher dose of nicotine in adolescent mice? It would be an additional and interesting information whether in adolescent mice the nicotine effect has already reached a saturated level or the LTP could further increase at higher concentration of nicotine.*

As now shown in [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}, similar LTP is produced in adolescent mice by both a low (0.4 mg/kg) and a high dose of nicotine (1 mg/kg), indicating that even at lower doses of nicotine the LTP reaches a plateau in adolescence.

*4) Although the nicotine-mediated effect on AMPAR/NMDAR ratio is clearly significant, the number of 4 observations is too low and only slightly above the minimal required number for the statistical power. Strong recommendation to increase the N.*

We agree with the reviewers and have increased the N. Even with a larger sample size, the conclusion of our work remained unchanged.

*5) The selection criteria of participants, especially smoker subjects, should be specified. Did they have history of any other drug dependence? A table depicting the participants\' demographics would be useful for readers.*

As suggested by the reviewers, we have now provided a supplemental figure that includes two tables with relevant information about our subjects (demographic, gender and age of the individuals; see [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}).

6\) The presentation of the polymorphism data was confusing. Especially the relationship between the mouse work and human results should be made clear and caveats in the link pointed out. It is important to note that the strength of the paper is the connection between the mouse and human data and anything that would strengthen that connection would consequently strengthen the paper. The relation between FLUC and RLUC assays is also murky and confusing. This should also be explained better. Finally, the reviewers wonder which mechanisms could cause increased expression of Eif2s inhibits p-eIF2α−mediated translation.

As suggested by the reviewers, we have better explained the connection between the human and mouse data (subsection "Polymorphic variation in the Eif2s1 gene affects reward signaling measured by fMRI in human tobacco smokers", last paragraph). In addition, we have made clearer the description of the luciferase experiments (in the third paragraph of the aforementioned subsection).

Finally, in the Discussion section, we now hypothesize different mechanisms by which expression of Eif2s could block eIF2α−mediated translation (subsection "Polymorphic variation in the Eif2s1 gene affects reward signaling measured by fMRI in human tobacco smokers"). As this is beyond the scope of the current paper, our intention is to further investigate this process in detail and publish the results separately.
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